The anxiolytic potential and psychotropic side effects of an Echinacea preparation in laboratory animals and healthy volunteers

Phytotherapy Research

Volumn 27, Issue 1, 2013, Pages 54-61

  Haller, József ^a   Freund, Tamás F ^a   Pelczer, Katalin Gyimesi ^a   Füredi, János ^b   Krecsak, Laszlo ^c   Zámbori, János ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Mensana 2004 Psychiatry Clinic   (Hungary)

^c EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

anxiety; conditioned fear; elevated plus maze; side effects; State Trait Anxiety Inventory; toxicity

Indexed keywords

ECHINACEA ANGUSTIFLORA EXTRACT;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG MEGADOSE; EXPERIMENTATION; FEAR; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LOCOMOTION; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY; NONHUMAN; NORMAL HUMAN; OBSERVATIONAL STUDY; OPEN FIELD TEST; PATTERN RECOGNITION; PLACE PREFERENCE; PSYCHOTROPIC ACTIVITY; RAT; REWARD; SELF EVALUATION; STATE TRAIT ANXIETY INVENTORY; TOXICITY TESTING; TRANQUILIZING ACTIVITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINACEA; FEAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR; SELF-ASSESSMENT; TABLETS;

ANIMALIA; ECHINACEA ANGUSTIFOLIA; RATTUS;

EID: 84872091497     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4677     Document Type: Article

References (60)

1. Alpsoy E, Ozcan E, Cetin L, et al,. 1998. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol 38: 197-200.
2. Andreatini R, Sartori VA, Seabra ML, Leite JR,. 2002. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 16: 650-654.
3. Andrews G, Issakidis C, Carter G,. 2001. Shortfall in mental health service utilisation. Br J Psychiatry 179: 417-425.
4. Astin JA,. 1998. Why patients use alternative medicine: results of a national study. J Am Med Assoc 279: 1548-1553.
5. Bakker A, van Dyck R, Spinhoven P, van Balkom AJ,. 1999. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psych 60: 831-838.
6. Barna I, Soproni K, Arszovszki A, Csabai K, Haller J,. 2007. WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids. Behav Pharmacol 18: 515-520.
7. Barnes J, Anderson LA, Gibbons S, Phillipson JD,. 2005. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol 57: 929-954.
8. Barsy B, Mikics E, Barsvári B, Haller J,. 2011. The long-term impact of footshock stress on addiction-related behaviors in rats. Neuropharmacology 60: 267-273.
9. Beck CH, Fibiger HC,. 1995. Conditioned fear-induced changes in behavior and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment. J Neurosci 15: 709-720.
10. Beechey AP, Eltringham RJ, Studd C,. 1981. Temazepam as premedication in day surgery. Anaesthesia 36: 10-15.
11. Ben-Arye E, Frenkel M, Klein A, Scharf M,. 2008. Attitudes toward integration of complementary and alternative medicine in primary care: perspectives of patients, physicians and complementary practitioners. Patient Educ Couns 70: 395-402.
12. Berghout CC, Zevalkink J,. 2008. Identifying clinical cases among patients assigned to psychoanalytic treatment. Bull Menninger Clin 72: 163-178.
13. Birt DF, Widrlechner MP, Lalone CA, et al,. 2008. Echinacea in infection. Am J Clin Nutr 87: 488S-492S.
14. Borchers AT, Keen CL, Stern JS, Gershwin ME,. 2000. Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr 72: 339-347.
15. Bourin M, Bougerol T, Guitton B, Broutin E,. 1997. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol 11: 127-132.
16. Brenes GA, Guralnik JM, Williamson J, Fried LP, Penninx BW,. 2005. Correlates of anxiety symptoms in physically disabled older women. Am J Geriatr Psych 13: 15-22.
17. Cukor D, Coplan J, Brown C, Peterson RA, Kimmel PL,. 2008. Course of depression and anxiety diagnosis in patients treated with hemodialysis: a 16-month follow-up. Clin J Am Soc Nephrol 3: 1752-1758.
18. De Candia MP, Di Sciascio G, Durbano F, et al,. 2009. Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder. Clin Ther 31: 2851-2859.
19. Delle Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M,. 1995. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 15: 12-19.
20. Dyson GJ, Thompson K, Palmer S, Thomas DM, Schofield P, 2012. The relationship between unmet needs and distress amongst young people with cancer. Support Care Cancer 20: 75-85.
21. Giordano J, Boatwright D, Stapleton S, Huff L,. 2002. Blending the boundaries: steps toward an integration of complementary and alternative medicine into mainstream practice. J Altern Complement Med 8: 897-906.
22. Giudicelli JF, Berdeaux A, Idrissi N, Richer C,. 1978. Clazepam: pharmacokinetics and effects on performance. Br J Clin Pharmacol 5: 65-69.
23. Hájos N, Holderith N, Németh B, et al,. 2011. The effects of an Echinacea preparation on synaptic transmission and the firing properties of CA1 pyramidal cells in the hippocampus. Phytother Res 26 (3): 354-362. doi: 10.1002/ptr.3556.
24. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF,. 2002. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395-1398.
25. Haller J, Hohmann J, Freund TF,. 2010. The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. Phytother Res 24: 1605-1613.
26. Haller J, Nagy R, Toth M, Pelczer KG, Mikics E,. 2011. NR2B subunit-specific NMDA antagonist Ro25-6981 inhibits the expression of conditioned fear: a comparison with the NMDA antagonist MK-801 and fluoxetine. Behav Pharmacol 22: 113-121.
27. Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H,. 2008. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 15: 2-15.
28. Hohmann J, Rédei D, Forgo P, et al,. 2011. Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Phytochemistry 72: 1848-1853.
29. Imlah NW,. The episodic nature of anxiety and its treatment with oxazepam 1978. Acta Psychiatr Scand Suppl 274: 94-98.
30. Izzo AA, Ernst E,. 2001. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61: 2163-2175.
31. Kim WK, Jung JW, Ahn NY, et al,. 2004. Anxiolytic-like effects of extracts from Albizzia julibrissin bark in the elevated plus-maze in rats. Life Sci 75: 2787-2795.
32. Kumar S, Sharma A,. 2005. Anti-anxiety activity studies on homoeopathic formulations of Turnera aphrodisiaca Ward. Evid Based Complement Alternat Med 2: 117-119.
33. Laakmann G, Schüle C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S,. 1998. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136: 357-366.
34. Lemoine P, Rouillon F, Pouget D,. 1996. Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders. Encéphale 22: 461-467.
35. Mancebo MC, Pinto A, Rasmussen SA, Eisen JL,. 2008. Development of the Treatment Adherence Survey-patient version (TAS-P) for OCD. J Anxiety Disord 22: 32-43.
36. McCurdy L,. 1984. Benzodiazepines in the treatment of acute anxiety. Curr Med Res Opin 8 Suppl 4: 115-119.
37. Mengs U, Clare CB, Poiley JA,. 1991. Toxicity of Echinacea purpurea. Acute, subacute and genotoxicity studies. Arzneimittelforschung 41: 1076-1081.
38. Miyamoto J, Tsuji M, Takeda H, Nawa H, Matsumiya T,. 2000. Pretreatment with diazepam suppresses the reduction in defensive freezing behavior induced by fluvoxamine in the conditioned fear stress paradigm in mice. Eur J Pharmacol 409: 81-84.
39. Pande AC, Crockatt JG, Feltner DE, et al,. 2003. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160: 533-540.
40. Pellow S, Chopin P, File SE, Briley M,. 1985. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
41. Piomelli D, Tarzia G, Duranti A, et al,. 2006. Pharmacological profi le of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12: 21-38.
42. Rabbani M, Sajjadi SE, Jalali A,. 2005. Hydroalcohol extract and fractions of Stachys lavandulifolia Vahl: effects on spontaneous motor activity and elevated plus-maze behaviour. Phytother Res 19: 854-858.
43. Reginatto FH, De-Paris F, Petry RD, et al,. 2006. Evaluation of anxiolytic activity of spray dried powders of two South Brazilian Passiflora species. Phytother Res 20: 348-351.
44. Rex A, Morgenstern E, Fink H,. 2002. Anxiolytic-like effects of kava-kava in the elevated plus maze test-a comparison with diazepam. Prog Neuropsychopharmacol Biol Psych 26: 855-860.
45. Rickels K, Schweizer E,. 1997. The clinical presentation of generalized anxiety in primary-care settings: practical concepts of classification and management. J Clin Psych 58 (Suppl 11): 4-10.
46. Rickels K, Schweizer E,. 1998. The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment. Br J Psych 34: 49-54.
47. Rickels K, Pollack MH, Feltner DE, et al,. 2005. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62: 1022-1030.
48. Rouillon F,. 2004. Long term therapy of generalized anxiety disorder. Eur Psych 19: 96-101.
49. Shikanai H, Izumi T, Matsumoto M, et al,. 2010. Diazepam-induced increases of synaptic efficacy in the hippocampal-medial prefrontal cortex pathway are associated with its anxiolytic-like effect in rats. J Pharmacol Sci 114: 341-346.
50. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK,. 2006. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 67: 1792-1800.
51. Sipos K, Sipos M,. 1978. The development nd validation of the Hungarian form of the STAI. In Cross-Cultural Anxiety, 2nd edn, Spielberger CD, Guerrero D, (eds). Hemisphere Publishing: Washington, 51-61.
52. Smith C,. 2011. The effects of Sceletium tortuosum in an in vivo model of psychological stress. J Ethnopharmacol 133: 31-36.
53. Spielberger CD, Gorsuch RL, Lushene RE,. 1970. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press: Palo Alto, CA.
54. Tesch BJ,. 2003. Herbs commonly used by women: an evidence based review. Am J Obstet Gynecol 188: S44-S55.
55. Thewissen V, Bentall RP, Oorschot M, et al,. 2011. Emotions, self-esteem, and paranoid episodes: an experience sampling study. Br J Clin Psychol 50: 178-195.
56. Tominaga K, Higuchi K, Iketani T, et al,. 2007. Comparison of gastrointestinal symptoms and psychological factors of functional dyspepsia to peptic ulcer or panic disorder patients. Inflammopharmacology 15: 84-89.
57. Wang PS, Aguilar-Gaxiola S, Alonso J, et al,. 2007. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet 370: 841-850.
58. Wislowska-Stanek A, Zienowicz M, Lehner M, et al,. 2005. Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus. Neurosci Lett 389: 115-120.
59. Wittchen HU, Jacobi F, Rehm J, et al,. 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 655-679.
60. Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP, Bauer R,. 2005. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med 71: 701-705.